Shares of Campbell Soup Company (CPB) soared to a new 52-week high of $46.54 on Tuesday, Apr 16, following its previous high of $46.45 reached on Apr 2. The company continues to gain from a consistent positive earnings surprise trend, strong revenue growth, impressive management guidance, an encouraging cash position and reasonable valuation levels.
Average volume of shares traded over the last 3 months stands at approximately 1,980K. Moreover, the stock currently trades at a forward P/E of 18.2x, at a 9.0% premium from the peer group average of 16.7x.
This Zacks Rank #2 (Buy) foods and simple meals manufacturer closed trade at $46.53 on Apr 16, representing a solid year-to-date return of approximately 29.5%, while gaining about 38.1% over the past one year.
Alongside, companies like The Clorox Company (CLX), The Walt Disney Company (DIS) and Colgate-Palmolive Co. (CL) crafted new 52-week highs of $89.66, $60.75 and $119.48, respectively on Tuesday.
Looking at its earnings surprise history, Campbell has beaten the Zacks Consensus Estimates consecutively over the past 8 quarters. The average positive surprise in the trailing 8 quarters comes to 7.1%.
The recent second-quarter fiscal 2013 results have added to its streak of upbeat performances. Campbell Soup posted earnings of 70 cents per share for second-quarter fiscal 2013, handily surpassing the Zacks Consensus Estimate of 66 cents, which led to a surprise of 6.1%. Moreover, quarterly earnings surged 9% year over year, primarily driven by a 10.5% rise in the top line.
Looking ahead, the company continues to anticipate sales growth in the range of 10%–12% and earnings between $2.51 and $2.57 per share in fiscal 2013, reflecting an increase of 3%–5% from 2012 level. The current Zacks Consensus Estimate stands at $2.55 per share.
Apart from strong results, Campbell’s growth story looks compelling. We believe the company’s prudent investment and strategic initiatives toward product innovation and brand building will boost its customer base and profitability.
Read the Full Research Report on CL
Read the Full Research Report on CPB
Read the Full Research Report on DIS
Read the Full Research Report on CLX
More From Zacks.com